All the latest recruitment agency news in Wales.
Swiss medical manufacturer CeQur is to launch a new Welsh subsidiary . The company has created a new insulin infusion device for people with type 2 diabetes.
Wales-based Arthurian Life Sciences provided funding together with Woodford Investment Management. Existing investors including Endeavour Vision, Schroder & Co Banque SA and VI Partners also participated.
The funding will also be used to support further clinical and regulatory activities, manufacturing scale-up and commercial operations for a planned European and US 2016 launch of the company’s three-day insulin infusion device, PaQ.
PaQ is a simple patch-like insulin infusion device which could potentially offer an alternative to insulin injections for people with type 2 diabetes.
Following the launch in Wales, CeQur will start a clinical study in collaboration with University of Swansea, scheduled to begin enrollment in 2016.
To read more visit the Arthrian Life Sciences website.